Research Capitl upgraded shares of Knight Therapeutics (TSE:GUD - Free Report) from a hold rating to a strong-buy rating in a report issued on Tuesday, March 11th,Zacks.com reports.
Separately, Raymond James raised shares of Knight Therapeutics to a "moderate buy" rating in a report on Friday, November 15th. Two analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Strong Buy" and a consensus target price of C$7.08.
Check Out Our Latest Report on Knight Therapeutics
Knight Therapeutics Trading Up 0.3 %
Shares of GUD stock traded up C$0.02 on Tuesday, hitting C$6.19. The stock had a trading volume of 80,863 shares, compared to its average volume of 68,294. Knight Therapeutics has a twelve month low of C$5.09 and a twelve month high of C$6.25. The firm has a market cap of C$626.12 million, a P/E ratio of -20.67, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The company has a fifty day moving average price of C$5.61 and a two-hundred day moving average price of C$5.56.
Insider Buying and Selling
In other news, insider Sime Armoyan bought 17,600 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of C$5.48 per share, with a total value of C$96,488.48. Company insiders own 45.62% of the company's stock.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Stories
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
